Bausch Health Companies (NYSE:BHC) Price Target Increased to $12.00 by Analysts at Royal Bank of Canada

Bausch Health Companies (NYSE:BHC - Free Report) had its price objective upped by Royal Bank of Canada from $9.00 to $12.00 in a report published on Friday, Benzinga reports. They currently have a sector perform rating on the stock.

A number of other analysts also recently weighed in on BHC. Jefferies Financial Group cut their target price on Bausch Health Companies from $16.00 to $14.00 and set a buy rating for the company in a research report on Tuesday, February 20th. StockNews.com upgraded Bausch Health Companies from a hold rating to a buy rating in a research report on Wednesday, February 7th.

Bausch Health Companies Price Performance

BHC traded up $0.36 during trading on Friday, hitting $10.41. The stock had a trading volume of 4,469,500 shares, compared to its average volume of 2,513,699. The company has a 50 day moving average price of $9.12 and a 200-day moving average price of $8.11. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of -6.43 and a beta of 0.85. Bausch Health Companies has a one year low of $5.57 and a one year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The company's revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.02 EPS. As a group, sell-side analysts predict that Bausch Health Companies will post 3.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors have recently modified their holdings of the business. Aviva PLC increased its holdings in Bausch Health Companies by 2.2% in the 1st quarter. Aviva PLC now owns 45,626 shares of the company's stock worth $1,044,000 after purchasing an additional 971 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Bausch Health Companies by 0.5% in the second quarter. CIBC Asset Management Inc now owns 267,868 shares of the company's stock worth $2,145,000 after purchasing an additional 1,428 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Bausch Health Companies by 0.5% in the third quarter. Legal & General Group Plc now owns 296,379 shares of the company's stock worth $2,455,000 after purchasing an additional 1,565 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Bausch Health Companies by 0.9% during the second quarter. The Manufacturers Life Insurance Company now owns 211,993 shares of the company's stock valued at $1,696,000 after acquiring an additional 1,945 shares during the last quarter. Finally, Gabelli Funds LLC increased its position in shares of Bausch Health Companies by 2.2% during the first quarter. Gabelli Funds LLC now owns 93,000 shares of the company's stock valued at $753,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.